Breaking News Instant updates and real-time market news.

BHVN

Biohaven Pharmaceutical

$24.39

-1 (-3.94%)

18:05
11/14/17
11/14
18:05
11/14/17
18:05

Biohaven Pharmaceutical reports Q3 EPS ($1.19), consensus ($1.10)

Reports cash as of September 30 was $175.8M. Cash as of December 31, 2016, prior to the Company's initial public offering, was $23.6M.

  • 28

    Nov

BHVN Biohaven Pharmaceutical
$24.39

-1 (-3.94%)

10/03/17
NEED
10/03/17
NO CHANGE
NEED
Biohaven Pharmaceutical price target lowered to $36 from $43 at Needham
Needham analyst Alan Carr cut his price target on Biohaven after the company's trigriluzole drug missed its primary endpoint in a Phase 2/3 trial. The analyst removed the drug from his model but remains upbeat on the outlook for the Phase 3 trial of the company's trigriluzole drug, whose data is due out in 1Q18. He keeps a Buy rating on the shares.
10/03/17
MSCO
10/03/17
NO CHANGE
Target $38
MSCO
Overweight
Biohaven price target lowered to $38 from $47 at Morgan Stanley
Morgan Stanley analyst Matthew Harrison removed spinocerebellar ataxia from his model for Biohaven Pharmaceutical after trigriluzole did not succeed in a Phase II/III study. However, given trigriluzole was not associated with any safety issues, he did not adjust his assumptions about the probability of success for the company's other three glutamate programs. Harrison lowered his price target on Biohaven to $38 from $47, but keeps an Overweight rating on the stock, adding that he believes positive data in Q1 from its migraine trial could push the stock into "the mid-$50s."
10/02/17
NEED
10/02/17
NO CHANGE
Target $36
NEED
Strong Buy
Biohaven target lowered to $36 on failed study at Needham
Needham analyst Alan Carr lowered his price target for Biohaven Pharmaceutical to $36 from $43 after the company reported the trigriluzole Phase 2/3 trial in spinocerebellar ataxia missed the primary endpoint. The analyst removed the program from his model but continues to expect a positive Phase 3 readout for rimegepant in Q1 of 2018. Carr keeps a Buy rating on Biohaven.
09/25/17
MSCO
09/25/17
NO CHANGE
Target $47
MSCO
Overweight
Biohaven price target raised to $47 from $28 at Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that Phase 2/3 data from trigriluzole in spinocerebellar ataxia, the lead program within Biohaven Pharmaceutical's glutamate platform, is expected in Q4. The analyst, who assigns a 75% chance of success, believes his previous estimates for trigriluzole in SCA were too conservative and now sees it reaching long-term share of about 50% given the lack of other therapies. He raised his price target on Biohaven to $47 from $28 and keeps an Overweigh rating on the stock.

TODAY'S FREE FLY STORIES

CIDM

Cinedigm

$1.39

0.02 (1.46%)

15:08
01/17/18
01/17
15:08
01/17/18
15:08
Hot Stocks
Cinedigm, Insurrection Entertainment announce North American distribution deal »

Cinedigm announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

AUPH

Aurinia Pharmaceuticals

$5.37

0.02 (0.37%)

15:06
01/17/18
01/17
15:06
01/17/18
15:06
Periodicals
Aurinia CEO open to takeover if voclosporin succeeds, Dealreporter says »

Aurinia Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USO

United States Oil Fund

$12.79

0.03 (0.24%)

15:00
01/17/18
01/17
15:00
01/17/18
15:00
Options
Put buying in US Oil Fund ahead of data »

Put buying in US Oil Fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:00
01/17/18
01/17
15:00
01/17/18
15:00
General news
Breaking General news story  »

Dallas Federal Reserve…

HIMX

Himax

$9.87

-0.83 (-7.76%)

14:59
01/17/18
01/17
14:59
01/17/18
14:59
Recommendations
Himax analyst commentary  »

Baird maintains Himax…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVGO

Broadcom

$263.25

-1.04 (-0.39%)

, QCOM

Qualcomm

$68.25

2.87 (4.39%)

14:51
01/17/18
01/17
14:51
01/17/18
14:51
Periodicals
Broadcom tells Bloomberg FTC review 'immaterial to business' »

In an emailed statement…

AVGO

Broadcom

$263.25

-1.04 (-0.39%)

QCOM

Qualcomm

$68.25

2.87 (4.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

PVG

Pretium Resources

$11.61

-0.04 (-0.34%)

14:45
01/17/18
01/17
14:45
01/17/18
14:45
Options
Pretium Resources call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:45
01/17/18
01/17
14:45
01/17/18
14:45
General news
Breaking General news story  »

Chicago Federal Reserve…

GOOG

Alphabet

$1,121.76

-0.5 (-0.04%)

, GOOGL

Alphabet Class A

$1,130.70

0.05 (0.00%)

14:39
01/17/18
01/17
14:39
01/17/18
14:39
Hot Stocks
Google introduces Cloud AutoML to help businesses use machine learning »

In a blog post, Google…

GOOG

Alphabet

$1,121.76

-0.5 (-0.04%)

GOOGL

Alphabet Class A

$1,130.70

0.05 (0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 23

    Jan

  • 01

    Feb

  • 01

    Feb

  • 07

    Feb

  • 28

    Feb

  • 18

    Mar

CBS

CBS

$59.44

0.01 (0.02%)

, VIAB

Viacom

$31.38

-2.38 (-7.05%)

14:37
01/17/18
01/17
14:37
01/17/18
14:37
Periodicals
Shari Redstone renews push to merge CBS, Viacom, WSJ reports »

Shari Redstone is…

CBS

CBS

$59.44

0.01 (0.02%)

VIAB

Viacom

$31.38

-2.38 (-7.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

  • 15

    Feb

JBHT

J.B. Hunt

$120.64

-0.42 (-0.35%)

14:35
01/17/18
01/17
14:35
01/17/18
14:35
Technical Analysis
Technical Earnings Preview: J.B. Hunt near life highs before earnings »

At time of writing and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XRX

Xerox

$31.91

-0.44 (-1.36%)

14:35
01/17/18
01/17
14:35
01/17/18
14:35
Hot Stocks
Deason reports 6% stake in Xerox, demands disclosure of JV pact with Fujifilm »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:35
01/17/18
01/17
14:35
01/17/18
14:35
General news
Treasury Action: yields held near highs »

Treasury Action: yields…

EXAS

Exact Sciences

$52.95

0.33 (0.63%)

, VNRX

VolitionRx

$2.95

0.0441 (1.52%)

14:31
01/17/18
01/17
14:31
01/17/18
14:31
Hot Stocks
Analysts stay bullish on Exact Sciences after ASCO abstract prompts pullback »

Shares of Exact Sciences…

EXAS

Exact Sciences

$52.95

0.33 (0.63%)

VNRX

VolitionRx

$2.95

0.0441 (1.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 26

    Feb

  • 29

    Mar

AG

First Majestic

$7.36

0.0106 (0.14%)

14:30
01/17/18
01/17
14:30
01/17/18
14:30
Options
Far upside call buyers in First Magestic as shares trade flat »

Far upside call buyers in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNO

Vornado

$71.16

-0.05 (-0.07%)

14:26
01/17/18
01/17
14:26
01/17/18
14:26
Hot Stocks
Vornado raises dividend to 63c per share »

Vornado Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALX

Alexander's

$379.05

-3.045 (-0.80%)

14:24
01/17/18
01/17
14:24
01/17/18
14:24
Hot Stocks
Alexander's boosts quarterly dividend to $4.50 per share »

Alexander's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$147.07

0.21 (0.14%)

14:22
01/17/18
01/17
14:22
01/17/18
14:22
Hot Stocks
USPTO board says Janssen Oncology patent claims unpatentable »

In a final written…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

LOCO

El Pollo Loco

$10.10

-0.2 (-1.94%)

14:20
01/17/18
01/17
14:20
01/17/18
14:20
Options
Bullish option flow in El Pollo Loco »

Bullish option flow in El…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:20
01/17/18
01/17
14:20
01/17/18
14:20
General news
Fed's Beige Book said the economy continued to expand »

Fed's Beige Book…

$NSD

NASDAQ Market Internals

14:17
01/17/18
01/17
14:17
01/17/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
01/17/18
01/17
14:16
01/17/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRSP

Crispr Therapeutics

$27.18

-1.34 (-4.70%)

14:12
01/17/18
01/17
14:12
01/17/18
14:12
Recommendations
Crispr Therapeutics analyst commentary  »

Piper says European…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$54.72

0.12 (0.22%)

14:12
01/17/18
01/17
14:12
01/17/18
14:12
Technical Analysis
Technical Earnings Preview: Morgan Stanley near 52-week high before news »

The stock has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

INTC

Intel

$43.14

-0.1 (-0.23%)

14:10
01/17/18
01/17
14:10
01/17/18
14:10
Options
Large block of puts in Intel as shares advance »

Large block of puts in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 24

    Jan

  • 25

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.